胰腺癌分子靶向治疗(Molecular targeted therapy for pancreatic cancer).doc

胰腺癌分子靶向治疗(Molecular targeted therapy for pancreatic cancer).doc

  1. 1、本文档共6页,可阅读全部内容。
  2. 2、原创力文档(book118)网站文档一经付费(服务费),不意味着购买了该文档的版权,仅供个人/单位学习、研究之用,不得用于商业用途,未经授权,严禁复制、发行、汇编、翻译或者网络传播等,侵权必究。
  3. 3、本站所有内容均由合作方或网友上传,本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺!文档内容仅供研究参考,付费前请自行鉴别。如您付费,意味着您自己接受本站规则且自行承担风险,本站不退款、不进行额外附加服务;查看《如何避免下载的几个坑》。如果您已付费下载过本站文档,您可以点击 这里二次下载
  4. 4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等,请点击“版权申诉”(推荐),也可以打举报电话:400-050-0827(电话支持时间:9:00-18:30)。
查看更多
胰腺癌分子靶向治疗(Molecular targeted therapy for pancreatic cancer)

胰腺癌分子靶向治疗(Molecular targeted therapy for pancreatic cancer) Molecular targeted therapy for pancreatic cancer Molecular targeted therapy According to tumor molecular events, that is, a tumor cell has a gene or its gene expression products (such as proteins, etc.) as the treatment Target reverses the malignant biological behavior of tumor from molecular level (such as proliferation, differentiation, recurrence, metastasis, chemotherapy, drug resistance, radiation resistance, and fine Apoptosis, neovascularization and so on, so as to achieve the purpose of prevention and treatment of tumors. In general, molecular targeting therapy targets the difference between tumor cells and normal cells, attacking only tumor cells and normal cells It sounded very small. Pancreatic cancer, molecular targeted therapy, drug classification EGFR monoclonal antibody targeting drug [tyrosine kinase inhibitors (EGFR-TKI)] Anti vascular endothelial growth factor (VEGF) targeting drugs Matrix metalloproteinase inhibitors (MMPIs) The farnesyl transferase inhibitor (FTIs) ? other molecular targeted therapies and immunotherapy drugs EGFR is a transmembrane receptor of tyrosine kinase, and plays a key role in cell growth, repair and functional differentiation. EGFR monoclonal antibody, It can competitively bind to the extracellular portion of EGFR, reduce phosphorylation by receptor ligand binding, and interfere with EGFR mediated signal transduction Pathway, thereby promoting apoptosis and inhibiting tumor growth and metastasis. At the same time, it can inhibit the blood indirectly by lowering VEGF and other related factors Guan Shengcheng and tumor metastasis. Study of EGFR monoclonal antibody targeting drug: Cetuximab (Cetuximab) combined with GEM: The initial dose of Cetuximab was 400mg/m2, first weeks, followed by 250mg/m2 per week for 7 consecutive weeks; GEM, 1000, mg/m2, and even Take 7 weeks for 1 weeks, and then GEM takes 3 weeks every 4 weeks, while Cetuximab is given 1 times a week Re

您可能关注的文档

文档评论(0)

f8r9t5c + 关注
实名认证
内容提供者

该用户很懒,什么也没介绍

版权声明书
用户编号:8000054077000003

1亿VIP精品文档

相关文档